A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

  • Beta-Thalassemia
Trial Status:

Completed

This trial runs in
Countries
  • Italy
  • Lebanon
  • Thailand
Trial Identifier:

NCT03271541 2016-004799-23 BP39642

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia. This study consists of two parts: Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose. Part 2 - Open Label Extension (OLE) - up to an additional 12 months. Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT03271541 , BP39642 , 2016-004799-23 Trial Identifier
      Bitopertin Treatments
      Beta-Thalassemia Condition
      Official Title

      A Phase II, Single Arm, Multicenter, Proof-of-Mechanism Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Βeta-Thalassemia

      Eligibility Criteria

      All Gender
      ≥ 18 Years & ≤ 55 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Confirmed diagnosis of beta-thalassemia
      • Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as Hb concentrations >7.5 grams per deciliter (g/dL) and <9.5 g/dL, less than or equal to 4 transfusions of red blood cell units within 1 year prior to study enrollment, and no transfusion within 12 weeks prior to study enrollment
      • Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more than 80% compliance from expected use of study medication (based on patient diary and study drug accountability; Part 2 only)
      • A favorable benefit-risk ratio from treatment with bitopertin as assessed by the Investigator (Part 2 only)
      Exclusion Criteria
      • Any history of gene therapy
      • History of hemolytic anemia except for beta-thalassemia
      • Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only)
      • Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment.
      • Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to enrollment (Part 1 only)
      • Depression, treatment with anti-depressants, or other psychiatric illnesses and/or drug abuse
      • Clinically significant/uncontrolled comorbid disease
      • Pregnant or breastfeeding females
      • Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or CYP3A4 inducers within 4 weeks prior to study drug
      • Active hepatitis B or C or known positive human immunodeficiency virus (HIV) test result
      • Diagnosis of cancer within previous 5 years unless treatment has resulted in complete freedom from disease for at least 2 years
      • Any major illness within 1 month or febrile illness within 1 week prior to study drug
      • Pulmonary hypertension requiring oxygen therapy (Part 1 only)

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now